Introduction
In the last decade, increasing resistance among Gram-positive bacteria, [1] [2] [3] including oxacillin-resistant staphylococci, vancomycin-resistant enterococci and penicillin-resistant streptococci, has emphasized the need for new, more potent, compounds effective against these organisms. Recent reports of staphylococci with increasing resistance to vancomycin have caused even more concern. 4 RWJ-54428 (MC-02 479) is a new parenteral cephalosporin (Microcide Pharmaceuticals, Inc., Mountain View, CA, USA), originally developed by the R. W. Johnson Pharmaceutical Research Institute (Raritan, NJ, USA), that has been shown to be active against resistant strains of staphylococci, enterococci and pneumococci. 5 In the present study, we investigated the activity of RWJ-54428 against recent isolates of Gram-positive bacteria and included strains of staphylococci with decreased susceptibility to vancomycin. The study focused primarily on more resistant organisms in each group and compared the in vitro activity of the new agent with the activity of other agents, such as penicillin and vancomycin, and also antibacterial agents with enhanced activity against this group of organisms, such as quinupristin/dalfopristin and linezolid.
Materials and methods

Bacteria tested
Strains of staphylococci, streptococci and enterococci were selected from the culture collection of the Centers for Disease Control and Prevention (CDC) to comprise a large number of resistant organisms. These included staphylococci resistant to oxacillin (confirmed by the presence of the mecA gene), streptococci resistant to penicillin and enterococci resistant to ampicillin. The total number of each species and the number of strains that were resistant to the selected antimicrobial agent noted above (indicated in brackets) were: 76 (40) Staphylococcus aureus, 50 (29) coagulase-negative staphylococci, 54 (44) Streptococcus pneumoniae, 22 (9) 
Antimicrobial agents
Broth microdilution plates were prepared for testing streptococci using amoxicillin 
MIC method
Testing was performed by the NCCLS broth microdilution method 6 using cation-adjusted Mueller-Hinton broth (Difco brand; BD Biosciences, Sparks, MD, USA; cations adjusted in house). For testing streptococcal and pneumococcal isolates, the plates were supplemented with 5% lysed defibrinated horse blood. Plates were prepared with all the agents except RWJ-54428 and frozen at -70°C. RWJ-54428 was prepared on each day of testing, diluted and then dispensed into wells just before inoculation. Size of inoculum (c. 5 × 10 5 cfu/mL) and length and conditions of incubation of all plates were as specified by the NCCLS. 6
Results
The MICs of the antimicrobial agents for staphylococci, enterococci and streptococci are shown in Table 1 Staphylococci RWJ-54428 was active against all staphylococci tested, including mecA-positive strains and strains with decreased susceptibility to vancomycin (data not shown), with MIC 90 s ≤ 2 mg/L. The only antimicrobial agent with greater activity than RWJ-54428 against mecA-positive S. aureus strains was quinupristin/dalfopristin; both quinupristin/dalfopristin and minocycline demonstrated comparable activity against mecApositive coagulase-negative staphylococci. For the seven S. aureus strains for which the oxacillin MICs were borderline (both β-lactamase mediated and MOD strains), the activity of RWJ-54428 was similar to that of other mecA-negative strains (data not depicted separately).
Enterococci
Of the 50 enterococci tested, 18 (all E. faecium) were penicillin resistant (MIC ≥ 16 mg/L). Of those 18 strains, 14 were also resistant to ampicillin and the MICs of RWJ-54428 for those 14 strains were 4-8 mg/L. For the four strains that demonstrated resistance to penicillin (MICs 16-32 mg/L) but susceptibility to ampicillin (MICs 4-8 mg/L), the MICs of RWJ-54428 were 1 mg/L. Therefore, there is better correlation of RWJ-54428 activity with ampicillin than with penicillin. Against the ampicillin-susceptible enterococci tested, RWJ-54428 demonstrated the best overall activity.
For the 29 strains possessing the vanA or vanB gene, the MIC range of RWJ-54428 was ≤0.06-8 mg/L, which was similar to the range for strains that did not possess a vancomycin resistance gene (0.25-8 mg/L). For the 10 E. gallinarum/E. casseliflavus strains that possessed the vanC gene, the MIC range of RWJ-54428 was 0.25-0.5 mg/L.
Streptococci
The MIC 90 s of RWJ-54428 for penicillin-susceptible, -intermediate and -resistant pneumococci were, respectively, 0.03, 0.5 and 1 mg/L. Likewise, for penicillin-intermediate or -resistant strains of viridans group streptococci, the MIC 90 was 1 mg/L. Based on MIC 90 s, trovafloxacin demonstrated greater activity against penicillin-resistant S. pneumoniae than RWJ-54428; however, RWJ-54428 was the most active 
Discussion
The novel cephalosporin, RWJ-54428, was shown in this study to be active against a wide range of multiply resistant Gram-positive pathogens, including oxacillin-resistant S. aureus (MRSA), vancomycin-resistant E. faecalis, ampicillinsusceptible E. faecalis and E. faecium, and penicillin-resistant pneumococci and streptococci. Ampicillin-resistant E. faecium appeared to be the one group of bacteria for which the MICs of RWJ-54428 were typically ≥4 mg/L. Most resistance to oxacillin in staphylococci is due to the presence of the mecA gene, which regulates production of a new penicillin-binding protein (PBP) with decreased affinity for β-lactam agents. The failure of most current β-lactam agents to adequately treat infections caused by mecA-positive strains is due to the failure of the agents to bind to this alternative PBP, called PBP2′ (or PBP2a). 7 RWJ-54428 is a parenteral cephalosporin that binds PBP2′ in staphylococci 5 and shows in vitro activity against other Gram-positive bacteria, as well as Haemophilus influenzae and Moraxella catarrhalis. 5 Conventional wisdom has held that MRSA should be considered resistant to all β-lactams and reported as such, [8] [9] [10] even though these organisms may appear to be susceptible when tested in vitro. Should RWJ-54428 or similar agents with increased affinity for PBP2′ eventually become available for treatment of resistant staphylococci, microbiologists will need to be re-educated regarding the testing and reporting of such compounds, to which MRSA would typically be reported as resistant based on oxacillin test results.
In summary, RWJ-54428 is a novel cephalosporin with broad in vitro activity against a variety of multiply resistant Gram-positive pathogens, including staphylococci, enterococci and pneumococci. Of the bacteria tested, the only group of organisms for which the MIC 90 was >2 mg/L was ampicillinresistant E. faecium. 
